Shire Appoints New Chairman: Susan Kilsby

In Partnering & Investment, Press Release by Cameron

Shire Susan Kilsby

Susan Kilsby as been named as successor to Matthew Emmens as chairman of  the UK based Shire Plc. US born Miss Kilsby, who’s been with Shire since 2011, now becomes the second female chairman of a FTSE 100 company.

Under Mr Emmen’s leadership, Shire went through a period of rapid expansion which saw key acquisitions such as rare disease specialist ViroPharma for $4.2 billion, as well as a share increase from £3 to £30.

But the road in front of Miss Kilsby looks to be rather different. Shire’s chief executive, Flemming Ornskovm, recently announced that, after selling off the skin repair developer Dermagraft at a loss of $650 million, that Shire would be looking to strength its pipeline through focusing on their key areas of neuroscience and rare diseases.

So what can we expect from Miss Kilsby in the coming years? Well, having spent thirty-three years at Credit Suisse, most of which was spent as European head of mergers and acquisitions, I wouldn’t be surprised if we saw Shire stepping up it’s level of investment in the orphan drugs industry. If Shire are to break their reliance on their attention deficit disorder (ADD) treatment Vyvanse, the company will need to strengthen their pipeline significantly.

“Having worked with Susan on the Board over the past few years I believe she is the ideal Chairman for Shire as the Company embarks on another new era of growth.”Matthew Emmens, Shire Chairman

Susan Kilsby has been with Shire since 2011. She graduated from Yale School of Management in 1984, and is currently acting as a non-executive director for Coca-Cola HBC, BBA Aviation Plc and Green Mountain Coffee Roasters.

Visit Shire or see the press release.